FDA records linked by MedtechLedger identify Botiss Biomaterials GmbH as the applicant on a traditional 510(k) premarket notification for the device trade-named Jason membrane. The filing carries product code NPL, regulation number 872.3930 and the Dental advisory committee, and the agency recorded a substantially equivalent decision. The manufacturer’s own product pages describe the same membrane as a native collagen barrier obtained from porcine pericardium, developed and manufactured for dental bone and tissue regeneration. [1][2][3]
The Jason membrane filing and its scope
The 510(k) record for K260132 lists Botiss Biomaterials GmbH as applicant, with a correspondence address in Zossen, Germany, and Elena Pies as contact. The device is named Jason membrane, classified under product code NPL with regulation number 872.3930, and reviewed by the Dental panel as a traditional submission not reviewed by a third party. The FDA database entry records receipt on 16 January 2026 and a substantially equivalent decision on 8 November 2026, with a summary statement. [1][2]
A separate FDA letter for K242817 addresses the same trade name, Jason membrane, under regulation number 21 CFR 872.3930, product code NPL and Class II, and states that the subject device has the identical intended use and indications for use as the predicate device and is substantially equivalent in materials, principle of operation and sterilization. The FDA PDF carries a 12 December 2025 date; its Re-block gives the submission Dated field as 28 March 2025 and the Received field as 12 November 2025. It is a distinct filing from K260132 and is not part of the linked portfolio snapshot. [5]
What the manufacturer says the membrane is
Botiss describes Jason membrane as a native collagen membrane obtained from porcine pericardium, developed and manufactured for dental bone and tissue regeneration. The manufacturer states that, despite low thickness, the membrane provides a naturally long barrier function based on the composition and structure of pericardial collagen fibers, and that preservation of the pericardium’s natural biomechanical properties gives handling characteristics such as tear resistance and surface adaptation. These are manufacturer statements, not FDA findings. [3][9]
The manufacturer’s references for those product statements include Rothamel et al. 2012 on biocompatibility and biodegradation of a native porcine pericardium membrane, Barbeck et al. 2015 on porcine dermis and pericardium-based non-cross-linked materials, and Braga-Vilela et al. 2008 on the extracellular matrix of porcine pericardium. A note on the product page attributes tear-resistance and suture pull-out force testing to data on file rather than a published study. [3][9]
The wider documented product range
The manufacturer’s membrane guide lists Jason membrane within a collagen membrane category alongside collprotect membrane, and lists synthetic options including non-resorbable permamem and resorbable NOVAMag membrane and NOVAMag SHIELD. The same navigation lists bone substitute materials grouped as xenografts, allografts and synthetics, a soft tissue substitute material named mucoderm, wound-support products collacone and collafleece, and fixation items including a titan pin set. [4]
The product catalog frames these items as a dental bone and tissue regeneration portfolio spanning soft tissue, hard tissue and education, and states that no single bone graft or soft tissue biomaterial suits all medical needs, biological situations and indications. The catalog and membrane pages are manufacturer-published material describing product categories; they do not establish clinical performance. [7][8]
How to read the filing record
The linked collection for this applicant contains one 510(k) record, and that single record carries a substantially equivalent decision. The record sample is the same one entry, so the sample decision count and the collection decision count coincide at one. These figures describe the filings retrieved as of 20 November 2026 and are not measures of total company sales, total portfolio size or safety performance. [1]
The applicant identity in the FDA records is Botiss Biomaterials GmbH. No parent company, brand owner or corporate affiliate is verified in these sources, and the Zossen address appears as a filing and correspondence address rather than a confirmed headquarters. Product availability, distribution arrangements and certifications are not established by the cited records. [1][2][5]
